Because this PBM treatment protocol has already been shown to reduce oligomeric tau in the 12-month-old 3xTg-AD mouse [35], and our immunofluorescence analysis was incapable of differentiating between soluble oligomeric and insoluble fibrillar pTau, we employed a western blot technique in which we isolated only detergent-soluble hippocampal proteins and quantified pTau and total tau content using AT8 and Tau5, respectively. This evidence concerns the gene MAPT and Alzheimer disease.